Ipsen Extends Tender Offer for Albireo Pharma, Inc. to March 2023!

Ipsen S.A.’s Anemone Acquisition Corp. has extended their tender offer to purchase all of Albireo Pharma, Inc.’s outstanding shares of common stock, at a price of $42.00 per share and one non-transferable CVR per share, until Wednesday, 1 March 2023. Don’t miss out on this unique opportunity to own a piece of Albireo Pharma, Inc. for an attractive price!

Invest in our exclusive CVR and reap the rewards! You’ll receive a one-time cash payment of $10.00 for each CVR held, without interest and subject to any applicable taxes, when a certain milestone is achieved. To participate, simply fill in the Offer to Purchase from 23 January 2023 and submit the related Letter of Transmittal. Don’t miss out on this amazing opportunity!

The tender offer deadline has been extended to provide more time to satisfy the condition of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). This will ensure that all necessary steps have been taken before the offer closes.

As of 6:00 p.m. on 21 February 2023, Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, reported that over 13 million shares had been tendered into the offer, representing around 63% of all outstanding shares as of 20 January 2023. For those who have already tendered their shares, there is no need to take any further action as the tender offer has been extended.

Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A., have filed a Tender Offer Statement on Schedule TO with the United States Securities and Exchange Commission (SEC) on 23 January 2023, outlining the conditions that must be met in order to successfully complete the tender offer. All interested parties are encouraged to review the Statement and take the necessary steps to ensure that these conditions are fulfilled.

About Ipsen

Ipsen is a global biopharmaceutical leader, dedicated to transforming lives through innovative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3,0bn in FY2022, Ipsen offers its medicines in over 100 countries. Ipsen has a strong commitment to external innovation, as well as research and development in its cutting-edge technological platforms located in the leading biotechnological and life-science hubs of Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; and Shanghai, China. With around 5,000 colleagues worldwide, Ipsen is listed in Paris (Euronext: IPN) and the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

Leave a Comment